US FDA Moves To Codify Size-Based Threshold For Drugs To Be Deemed Biologics

Agency proposes to define by regulation which proteins previously approved as drugs will be deemed licensed biologics, and therefore potentially subject to biosimilars competition. Industry has opposed the size-based thresholds, preferring a structure-based approach.